Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
Upstream Bio will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug in CRSwNP at the EAACI 2026 Congress. The oral session on June 14, 2026, features a responder analysis examining clinically meaningful improvements in key disease measures.
Key figures
- Drug Name
- Verekitug
- Phase Of Trial
- Phase 2
- Conference
- EAACI 2026
- Indication
- chronic rhinosinusitis with nasal polyps (CRSwNP)
- Trial name
- VIBRANT
- Presentation type
- oral session
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.